<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04484922</url>
  </required_header>
  <id_info>
    <org_study_id>2001-062-1095</org_study_id>
    <nct_id>NCT04484922</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine Neuroprotection in Pediatric Cardiac Surgery</brief_title>
  <official_title>The Effect of Dexmedetomidine on Neuroprotection in Pediatric Cardiac Surgery Patients: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neurodevelopmental disability is the most significant complication for survivors of infant
      surgery for congenital heart disease. In this study we sought to determine if intraoperative
      continuous infusion of dexmedetomidine are associated with neurodevelopmental outcomes at 12
      months.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 25, 2020</start_date>
  <completion_date type="Anticipated">May 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bayley scales of Infant development</measure>
    <time_frame>1 year after the surgery</time_frame>
    <description>Developmental outcomes at each assessment and within each domain (cognitive, language, and motor) were classified as &quot;average&quot; if they were within 1 SD of the mean or higher (scores .85), &quot;at risk&quot; if they were 1 to 2 SD below the mean (scores 70-84), and &quot;delayed&quot; if they were .2SD below the mean (,70). The trajectory of development over time in each domain (cognitive, language, and motor)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>neurodevelopment biomarker</measure>
    <time_frame>intraoperative (before skin incision, end of hypothermia, end of cardiopulmonary bypass), 4 hours after end of surgery</time_frame>
    <description>plasma glial fibrillary acidic protein concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammation</measure>
    <time_frame>4 hours after end of surgery</time_frame>
    <description>level of IL-6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>acute kidney injury</measure>
    <time_frame>2 hours after end of cardiopulmonary bypass</time_frame>
    <description>urinary NGAL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>myocardial injury</measure>
    <time_frame>intraoperative (before skin incision, end of cardiopulmonary bypass), 4 hours after end of surgery, 24 hours after end of surgery</time_frame>
    <description>level of Troponin i</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anesthesia monitoring</measure>
    <time_frame>intraoperative (from anesthetic induction to end of surgery)</time_frame>
    <description>Bispectral index, end tidal sevoflurane</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fluid management</measure>
    <time_frame>intraoperative (from anesthetic induction to end of surgery)</time_frame>
    <description>amount of transfusion, ROTEMÂ® values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fluid management</measure>
    <time_frame>intraoperative (from anesthetic induction to end of surgery)</time_frame>
    <description>blood loss</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Congenital Heart Disease</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>continuous infusion of dexmedetomidine during the surgery</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>continuous infusion of normal saline during the surgery</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Neonates undergoing cardiac surgery

          -  Infants undergoing cardiac surgery with cardiopulmonary bypass

        Exclusion Criteria:

          -  STAT category 4,5

          -  staged operation (BT shunt, BCPS)

          -  surgery with deep hypothermic circulatory arrest

          -  aspartate transaminase &gt;100unit/L, alanine aminostrasferase &gt; 100 unit/L
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Year</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eun-hee Kim</last_name>
    <phone>+82-01-9933-5014</phone>
    <email>beloveun@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul national university hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 21, 2020</study_first_submitted>
  <study_first_submitted_qc>July 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2020</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Eun-hee Kim</investigator_full_name>
    <investigator_title>Clinical assistant professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

